fashion -WSS

fashion

author：entertainment 2025-09-28 18:20:44 - browse：118

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why some fertility treatments produce more boy babies

WSS

The woman behind the Dana Farber

AI models in health care face new federal disclosure requirements

Should insurance cover cosmetic surgery?

Spinal cord stimulation reduces pain in amputees, study finds

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Louisiana bill approved classifying abortion pills as controlled substances

hotspot

fashion

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Medical records are filled with copy

Unmasking the 'centricity' illusion in clinical trials

Novavax promises a turnaround & Lilly roils the obesity market

Congress: Prevent baby formula shortages by passing a new bill

Heart attack and stroke risk calculators need revising

FDA needs staff influx to meet gene therapy needs, Marks says

Guidelines to prevent youth baseball injuries need more muscle

Should insurance cover cosmetic surgery?

focus

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Achieving telehealth equity for people with hearing loss

Why we need mandatory labeling of GMO products

Congenital heart disease patients face new threat of heart failure

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Teach medical students about patients with intellectual disabilities

focus

Wikipedia

focus

focus